Research and analysis

Respiratory syncytial virus (RSV) maternal vaccination coverage in England: July 2025

Updated 27 November 2025

Applies to England

© Crown copyright 2025

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/rsv-maternal-vaccination-coverage-in-england/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-july-2025

Published 27 November 2025

HPR Volume 19

This report presents monthly vaccine coverage data for the maternal respiratory syncytial virus (RSV) immunisation programme in England, focusing on the period up to July 2025. This report includes vaccine coverage estimates for pregnant women who delivered in the 11th month of the maternal vaccination programme in July 2025.

Main points

The main messages of this report are:

  • 55.6% (22,958 out of 41,269) of women that reported giving birth during the survey month received an RSV vaccine
  • coverage varied by NHS commissioning region, with the highest coverage reported in the South East region (64.4%) and the lowest in the London region (47.3%) (Table 1)
  • coverage varied by ethnic group: the highest coverage was reported among Other ethnic group – Chinese (78.5%) and the lowest among Black or Black British – Caribbean (30.5%) (Table 2)

Help us improve this resource

This vaccine coverage report is in the process of being designated as an Official Statistics release. As part of this process, we are seeking feedback from users to ensure the publication meets your needs.

We would be grateful if you could take a few minutes to complete a short survey and share your views.

Please complete the survey.

Your input will play an important role in shaping the development of these publications. Thank you for your time and support.

Analysis of maternal RSV vaccine coverage

Maternal uptake of the RSV vaccine is assessed monthly to monitor the reach and impact of the national immunisation programme. Given the programme’s design, uptake is defined as the proportion of pregnant women who delivered in the reporting month and had received the RSV vaccine during pregnancy. This metric serves as a proxy for vaccine coverage by infant birth month, reflecting the extent of passive immunity conferred to newborns.

The monthly uptake trend among pregnant women who have delivered since the programme’s launch, alongside the total number of GP practice data, is presented in Figure 1. This trend shows that uptake increased in the first few months of the programme and has remained stable since January 2025.

Figure 1. RSV vaccine coverage (%) trend among pregnant women by month of delivery, measured in July 2025

To further explore variation in uptake, the coverage by commissioning region is shown in Table 1, while the breakdown of uptake by ethnicity is shown in Table 2.

Table 1. RSV vaccine coverage (%) in pregnant women, measured in July 2025 by NHS commissioning region

Commissioning region RSV coverage (%)
London 47.3
Midlands 50.7
East of England 57.8
North West 53.9
North East and Yorkshire 56.8
South East 64.4
South West 62.9

Table 2. RSV vaccine coverage (%) in pregnant women, measured in July 2025 by ethnicity

Ethnic group RSV coverage (%)
Black or Black British - Caribbean 30.5
Black or Black British - Any other Black background 37.3
Mixed - White and Black Caribbean 37.9
Asian or Asian British - Pakistani 38.6
Any other Ethnic Group 43.7
White - Any other White background 44.6
Asian or Asian British - Bangladeshi 45.0
Black or Black British - African 45.2
Mixed - White and Black African 47.4
Ethnicity not stated 49.6
Mixed - Any other Mixed Background 50.5
Asian or Asian British - Any other Asian background 55.1
Patients with any other Ethnicity Code 55.2
White - Irish 61.2
White - British 61.9
Mixed - White and Asian 62.7
Asian or Asian British - Indian 64.1
Other Ethnic Group - Chinese 78.5

Uptake figures

This monthly report presents RSV vaccine coverage for women who delivered in the eleventh month of the RSV vaccination programme in July 2025.

Overall, the monthly RSV maternal vaccine coverage for July 2025 was 55.6%. In addition, this report reveals notable differences in coverage with uptake across regions differing by 17.1 percentage points. There is also a gap of nearly 48.0 percentage points observed in the uptake between ethnic groups.

This month’s report includes data from both GP IT suppliers, significantly expanding the data available in previous reports. It includes data from 99.2% of GPs in England, up from 40.4% of participating GPs previously in the first 4 months (September to December 2024) of the vaccination programme. This has been made possible by improvements in data quality and permits a more representative analysis of coverage and trends across England.

Since the RSV maternal vaccination programme has now been running for 10 months (up to the reporting month), an increasing number of pregnant women are receiving the vaccine during their eligible window. This growing awareness and notification from gestation week 20 onwards have contributed to a gradual increase in monthly vaccine uptake from 40.5% in September 2024 to the current figure reported for July 2025. As the programme continues and more women are informed earlier in their pregnancies, monthly vaccination coverage is expected to gradually increase.

Data sources and methodology

The maternal RSV vaccination report will be released monthly, presenting vaccination uptake data only for the specific reporting month, without cumulative figures from previous months. The reporting period for the current report is from 1 July to 31 July 2025. This report focuses on pregnant women who delivered in the survey month, regardless of gestational age at birth.

GP-level RSV vaccine coverage data is automatically uploaded via participating GP IT suppliers to the ImmForm website each month. ImmForm data is validated and analysed by the UK Health Security Agency (UKHSA) to check data completeness, query any anomalous data and describe epidemiological trends.

Since September 2024, the reporting data collected includes:

  • denominator: number of women who delivered in the survey month, excluding miscarriages and stillbirths, regardless of gestational age
  • numerator: number of women receiving RSV vaccination from week 28 of pregnancy up until delivery
  • refusals: number of women in the denominator who refused RSV vaccination between week 28 of pregnancy and delivery

To ensure accurate denominators are extracted from GP IT systems by the automated survey and precise coverage estimates are calculated, the methodology uses a monthly data extraction process with a 3-month reporting lag to allow enough time for relevant information to be recorded. For example, data from September 2024 was extracted on December 1, 2024.

The data presented in this report for July 2025 is based on data received from all GP IT suppliers, accounting for 99.2% of all national GP practices participating during the reporting month.

The August 2025 maternal RSV vaccination coverage report is scheduled to be released on 15 December 2025.                                                                

Background information

The RSV vaccine has been offered to pregnant women in England since September 2024 to address the significant burden of RSV-related illness, hospitalisations and deaths, particularly among infants under 6 months of age and older adults, who are at increased risk of lower respiratory tract infection (LRTI) (see the Green Book on immunisation).

In 2023, the Joint Committee on Vaccination and Immunisation (JCVI) issued a full statement recommending the implementation of a maternal RSV vaccination programme. This recommendation was based on robust evidence demonstrating the safety and effectiveness of RSV vaccines in protecting infants during their most vulnerable period.

The vaccine is recommended as a year-round programme to be administered from 28 weeks of gestation onwards. This timing aligns with the optimal window for passive antibody transfer to the foetus, ensuring effective protection against severe RSV-related illness. From 1 September 2024 (the programme start date), all women who are at least 28 weeks pregnant are advised to receive the vaccine as soon as possible, with vaccination continuing to be recommended for all eligible women throughout pregnancy up until delivery. Additionally, the vaccine will be reoffered for every subsequent pregnancy to maintain consistent coverage and protection.

This monthly report includes vaccine coverage data for women who delivered in July 2025.

Programme delivery

The programme is delivered through GP and maternity services, ensuring accessible vaccination opportunities for eligible pregnant women across England. In addition, the RSV vaccine is available through the community pharmacy delivery model at approximately 37 sites across 2 integrated care boards (ICBs) in the East of England. It is also available at up to 200 additional community pharmacy sites across the Midlands, North West, and South West Commissioning regions during the 2025 to 2026 expansion phase.

Previous monthly reports for RSV maternal vaccination coverage in England are available.

Further information and contact details

Feedback and contact information

For feedback or any enquiries relating to this document and the RSV vaccination coverage, please contact rsv@ukhsa.gov.uk

Back to top